Prelude Therapeutics Incorporated
PRLD
$4.66
$0.020.43%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 12.14M | 10.50M | 7.00M | 7.00M | 7.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.14M | 10.50M | 7.00M | 7.00M | 7.00M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 12.14M | 10.50M | 7.00M | 7.00M | 7.00M |
| SG&A Expenses | 22.31M | 23.62M | 26.33M | 27.58M | 28.72M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 115.41M | 131.55M | 142.01M | 146.98M | 146.71M |
| Operating Income | -103.27M | -121.05M | -135.01M | -139.98M | -139.71M |
| Income Before Tax | -99.50M | -111.77M | -124.32M | -127.83M | -127.17M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -99.50 | -111.77 | -124.32 | -127.83 | -127.17 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -99.50M | -111.77M | -124.32M | -127.83M | -127.17M |
| EBIT | -103.27M | -121.05M | -135.01M | -139.98M | -139.71M |
| EBITDA | -101.56M | -119.27M | -133.25M | -138.20M | -137.94M |
| EPS Basic | -1.30 | -1.47 | -1.64 | -1.68 | -1.68 |
| Normalized Basic EPS | -0.80 | -0.92 | -1.02 | -1.05 | -1.05 |
| EPS Diluted | -1.30 | -1.47 | -1.64 | -1.68 | -1.68 |
| Normalized Diluted EPS | -0.80 | -0.92 | -1.02 | -1.05 | -1.05 |
| Average Basic Shares Outstanding | 307.82M | 303.98M | 303.70M | 303.47M | 303.22M |
| Average Diluted Shares Outstanding | 307.82M | 303.98M | 303.70M | 303.47M | 303.22M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |